Atara Biotherapeutics (ATRA) Cash from Financing Activities (2013 - 2026)

Atara Biotherapeutics has reported Cash from Financing Activities for 14 years, with the latest figure at $3.0 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 1280.4% year-over-year to $3.0 million; the trailing twelve-month figure through Mar 2026 stood at $19.3 million (down 44.69% YoY), and the FY2025 full-year result was $16.1 million, down 72.85% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $3.0 million, up from -$3000.0 in the prior quarter.
• The five-year high for Cash from Financing Activities was $35.8 million in Q3 2024, with the low at -$328000.0 in Q4 2024.
• Historically, Cash from Financing Activities has averaged $7.8 million across 5 years, with a median of $1.0 million in 2025.
• The largest YoY upside for Cash from Financing Activities was 17308.17% in 2024 against a maximum downside of 168.79% in 2024.
• Atara Biotherapeutics' Cash from Financing Activities stood at $32.3 million in 2022, then slumped by 95.32% to $1.5 million in 2023, then sank by 121.69% to -$328000.0 in 2024, then soared by 99.09% to -$3000.0 in 2025, then soared by 98466.67% to $3.0 million in 2026.
• The last three Cash from Financing Activities figures came in at $3.0 million (Q1 2026), -$3000.0 (Q4 2025), and $1.0 million (Q3 2025), per Business Quant data.